1. Viral Vectors (Drug Substance)
Source Main cost driver for gene therapies; Ultragenyx uses AAV-based gene therapies and has in-house manufacturing in MA, also uses CMOs.
Confidence: high
RARE
T3Ultragenyx Pharmaceutical Inc.
Loading chart…
OverviewUltragenyx Pharmaceutical Inc. discovers, develops, and commercializes treatments for rare genetic conditions globally. Its marketed products, including Crysvit
Ultragenyx Pharmaceutical Inc. discovers, develops, and commercializes treatments for rare genetic conditions globally. Its marketed products, including Crysvita, Dojolvi, Evkeeza, Mepsevii, and newly approved GENGLYCOS for GSD 1A, generated $214 million in Q2 2026. The company anticipates a potential gene therapy launch for Sanfilippo A (PDUFA September 19th), with key Angelman syndrome data also expected. Ultragenyx aims for profitability by 2027.
Key Inputs And Sourcing
2. Cell Culture Media & Reagents
Source Essential for cell growth and protein production in biologics and gene therapy manufacturing.
Confidence: high
3. Specialized Resins & Membranes
Source Critical for downstream purification processes in biomanufacturing.
Confidence: medium
4. Skilled Labor
Source Required for complex biomanufacturing, QA/QC, and cleanroom operations.
Confidence: high
5. Licensing & Royalty Fees
Source Can be a primary cost driver for gene therapies, structured as a percentage of sales. Ultragenyx has numerous collaboration and licensing agreements.
Confidence: medium
6. Energy/Utilities
Source Required for operating GMP facilities, bioreactors, and other manufacturing equipment.
Confidence: medium
7. Specialized Equipment & Facility Maintenance
Source High capital investment in GMP facilities and specialized equipment for biomanufacturing.
Confidence: medium
8. Packaging Components
Source Necessary for sterile fill-finish and distribution of drug products.
Confidence: medium
9. Logistics & Distribution
Source Transporting sensitive biologic products from manufacturing sites to global customers.
Confidence: medium
10. Quality Control Testing
Source Essential for ensuring product quality and regulatory compliance throughout the manufacturing process.
Confidence: medium
Industry Publications
- Fierce Pharma (fiercepharma.com) — Comprehensive coverage of pharmaceutical industry news, M&A, clinical trials, and regulatory updates relevant to Ultragenyx's pipeline and commercial products. [cite: Theme_Overview]
- STAT News (statnews.com) — In-depth reporting on biotech, pharma, health policy, and scientific breakthroughs, offering broad industry context and specific rare disease developments. [cite: Theme_Overview]
- Endpoints News (endpts.com) — Niche news site providing focused coverage on biotech and pharma, including clinical trial results, regulatory decisions, and company-specific news. [cite: Theme_Overview]
- BioPharma Dive (biopharmadive.com) — Provides news and analysis on the biopharmaceutical industry, including gene therapy and rare disease developments, directly relevant to Ultragenyx's focus.
- CheckRare (checkrare.com) — Specializes in rare disease news, insights, and clinical perspectives, offering highly targeted information for a company like Ultragenyx.
Economic Data Watch
1. FRED — Federal Funds Effective Rate
Metric/field DFF
Cadence daily
Why it matters Affects borrowing costs for R&D, M&A, and overall company financing, impacting investment decisions and profitability.
Signal to watch Lower rates are generally favorable for financing and growth initiatives.
Confidence: high
2. FRED — Personal Consumption Expenditures: Health Care
Metric/field PCEHC
Cadence monthly
Why it matters Broader indicator of overall healthcare spending, reflecting the market size and patient capacity for high-cost rare disease therapies.
Signal to watch Increasing PCEHC suggests a growing and robust healthcare market.
Confidence: medium
3. FRED — Consumer Price Index for All Urban Consumers: Medical Care
Metric/field CPIMEDSL
Cadence monthly
Why it matters Tracks inflation specifically in medical care, influencing drug pricing, reimbursement discussions, and operational costs.
Signal to watch Stable or moderate growth in medical CPI is generally favorable, avoiding excessive pricing pressure.
Confidence: medium
4. FRED — Unemployment Rate
Metric/field UNRATE
Cadence monthly
Why it matters General economic health indicator; lower unemployment often correlates with better insurance coverage and patient access to healthcare, including specialized therapies.
Signal to watch Decreasing unemployment rates are a positive signal for patient access and market stability.
Confidence: medium
5. FRED — Federal Government Current Expenditures: Health
Metric/field FGEXPHEALTH
Cadence quarterly
Why it matters Reflects government commitment and spending on health, indirectly impacting funding and reimbursement policies for rare disease treatments and high-cost gene therapies.
Signal to watch Increasing government health expenditures could signal a supportive regulatory and reimbursement environment.
Confidence: medium
Free Alt Data Watch
1. Google Trends — Search Interest
Metric/field Angelman syndrome (search term)
Cadence weekly
Why it matters Monitors public and caregiver interest in Angelman syndrome, highly relevant with the upcoming GTX-102 Phase 3 data readout.
Signal to watch An increase in search interest could signal growing disease awareness and potential future demand for treatment.
Confidence: high
2. Google Trends — Search Interest
Metric/field Sanfilippo syndrome (search term)
Cadence weekly
Why it matters Tracks public and caregiver interest in Sanfilippo syndrome, crucial around the UX-111 PDUFA date of September 19, 2026.
Signal to watch An increase in search interest could signal growing disease awareness and potential future demand for treatment.
Confidence: high
3. FDA.gov — Official Announcements
Metric/field PDUFA action date for UX111 (rebisufligene etisparvovec)
Cadence event_driven
Why it matters Provides the direct regulatory outcome for UX111, a significant near-term catalyst for Ultragenyx.
Signal to watch FDA approval would be a strong positive signal for market entry and revenue generation.
Confidence: high
4. ClinicalTrials.gov — Study Status Updates
Metric/field GTX-102 ASPIRE study (NCT04259281) status and results posting
Cadence event_driven
Why it matters Tracks the progress of the pivotal Phase 3 ASPIRE study for Angelman syndrome, leading up to the top-line data readout expected in September or October 2026.
Signal to watch A status change to 'results posted' or similar, indicating data availability, would be a key signal.
Confidence: high
5. Reddit — r/rarediseases discussion volume and sentiment
Metric/field discussion volume and sentiment for Ultragenyx products/diseases (e.g., GSDIa, Sanfilippo, Angelman)
Cadence daily
Why it matters Gauges patient and caregiver community sentiment and discussion around Ultragenyx's existing products and pipeline, offering qualitative insights into real-world perception and demand.
Signal to watch Increased positive discussion or engagement around specific diseases or therapies would be a bullish signal.
Confidence: medium
Paid Alt Data Watch
1. IQVIA/Symphony Health — Prescription Data
Metric/field New Prescriptions (NRx) and Total Prescriptions (TRx) for Genglycos (DTX-401)
Cadence weekly
Why it matters Tracks the early commercial uptake and patient adoption of Ultragenyx's newly approved gene therapy for GSDIa, indicating launch success.
Signal to watch A strong and consistent NRx/TRx trend indicates successful market penetration and patient access.
Confidence: high
2. IQVIA/Symphony Health — Prescription Data
Metric/field New Prescriptions (NRx) and Total Prescriptions (TRx) for Crysvita
Cadence weekly
Why it matters Monitors the ongoing commercial performance and growth of Ultragenyx's established product, Crysvita, which is a significant revenue driver.
Signal to watch Consistent growth in NRx/TRx for Crysvita is a positive signal for sustained revenue.
Confidence: high
3. EvaluatePharma — Pipeline & Sales Forecasts
Metric/field Pipeline valuations and sales forecasts for Ultragenyx's gene therapy assets (Genglycos, UX111, GTX-102) and key competitors in rare diseases
Cadence quarterly
Why it matters Provides competitive intelligence and long-term revenue potential assessments for RARE's key pipeline products, reflecting market expectations and competitive positioning.
Signal to watch Upward revisions to forecasts for RARE's assets would be a positive signal.
Confidence: high
4. Claims Data (e.g., Komodo Health) — Patient Diagnoses and Treatment Patterns
Metric/field Diagnosed patient counts and treatment initiation rates for Sanfilippo A syndrome and Angelman syndrome
Cadence quarterly
Why it matters Helps to estimate the addressable market size and patient identification rates for UX111 (if approved) and GTX-102, informing commercial strategy and potential revenue.
Signal to watch Stable or increasing diagnosed patient counts and treatment initiation rates are favorable for future market penetration.
Confidence: medium
5. Physician Survey Data (e.g., Spherix Global Insights) — Physician Awareness and Prescribing Intent Surveys
Metric/field Physician prescribing intent and awareness levels for Genglycos (DTX-401) and UX111 (if approved)
Cadence quarterly
Why it matters Offers early insights into physician adoption and awareness of Ultragenyx's new gene therapies, indicating potential commercial success and market acceptance.
Signal to watch High prescribing intent and increasing awareness among target physicians are positive signals for launch trajectory.
Confidence: medium
Search Keywords Brand Product
- Crysvita
- DOJOLVI
- Evkeeza
- MEPSEVII
- GENGLYCOS gene therapy
- DTX-401 GSD Ia
- UX-111 Sanfilippo syndrome
- GTX-102 Angelman syndrome
- apazunersen
- setrusumab osteogenesis imperfecta
- rare genetic diseases treatment
- gene therapy development
- antisense oligonucleotide therapy
- enzyme replacement therapy
- biopharmaceutical commercialization
- orphan drugs
Search Keywords Event Phrases
- Ultragenyx Q2 2026 earnings
- DTX-401 approval
- UX-111 PDUFA
- GTX-102 ASPIRE data readout
Search Keywords Policy Regulatory
- FDA approval
- PDUFA date
- BLA submission
- marketing authorization
- National Health Insurance Japan
- What They Do (Plain English & Analogies)
- Ultragenyx is a biotechnology company that creates and sells medicines for very rare genetic diseases. Imagine a disease so uncommon that only a few thousand people in the world have it, and often there's no good treatment available. Ultragenyx steps in to develop these specialized treatments, often using advanced methods like gene therapy, which aims to fix the underlying genetic problem. They're like a highly specialized mechanic for very rare car models, building custom parts (medicines) to get them running properly when no one else can.
- Very Brief History
- Founded in 2010, Ultragenyx Pharmaceutical Inc. has rapidly grown into a biopharmaceutical firm focused on rare and ultra-rare genetic conditions. Over the years, it has built a diverse portfolio of approved therapies and a robust pipeline, including several gene therapies, aiming to address significant unmet medical needs.
- "Street Stereotype"
- Ultragenyx is generally perceived by investors and analysts as a leading player in the rare disease space, particularly with a strong focus on gene therapy and other innovative treatments for conditions with high unmet needs. The "street" likely views them as a growth-oriented biotech company with significant binary catalysts (PDUFA dates, clinical trial readouts) that could drive substantial value, but also with the inherent risks associated with drug development and commercialization in specialized markets. The recent gene therapy approval for GSDIa (GENGLYCOS™) and upcoming potential approvals reinforce their position as an innovator in this field.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Ultragenyx's customers are primarily healthcare providers, hospitals, and specialized treatment centers that care for patients with rare and ultra-rare genetic diseases. These also include government health programs and private insurers who cover the cost of these specialized therapies. No specific client companies are named in the transcript, as their products are typically prescribed by physicians and reimbursed by healthcare systems rather than sold directly to large corporate clients.
- New Customers / Segments They'Re Targeting
- Ultragenyx is actively targeting new patient populations for its investigational gene therapies. Specifically, they are preparing for the potential launch of DTX-401 (now GENGLYCOS™) for patients with Glycogen Storage Disease Type Ia (GSD Ia) and UX-111 for patients with Sanfilippo syndrome type A. These represent entirely new segments for their gene therapy portfolio, addressing diseases with significant unmet needs. They are also expanding geographically for existing products, such as DOJOLVI in Japan and the MENA region.
- Sales Geographies And Expansion Plans
- Ultragenyx currently sells its products in North America, Europe, Latin America (including Brazil and Argentina), Turkey, and the MENA region (with recent marketing authorization in Kuwait). They have also recently begun treating patients with DOJOLVI in Japan. The company is preparing for global launches of its first two potential gene therapies, GENGLYCOS™ (DTX-401) and UX-111, indicating a continued global expansion strategy for new approved products.
- How Key Themes May Help/Hurt
- **Help:** * **Biotech '26: Established Pharma (Bull1 & Bull2):** Ultragenyx aligns with the "leveraging cutting-edge research in genomics and personalized medicine" and "robust pipeline for rare disease treatments and therapies targeting niche markets" aspects. Their gene therapy programs (DTX-401, UX-111) and ASO program (GTX-102) are prime examples of cutting-edge research. The high-margin opportunities in rare diseases are a direct benefit. * **Rare Diseases '25: Gene Therapy & Genetic Med (Bull1, Bull2, Bull3):** This theme directly supports Ultragenyx. The "$2K Medicare Cap" (Bull1) could significantly expand the eligible patient pool for their high-priced gene therapies, accelerating revenue. The "FDA Is Actively Streamlining Gene Therapy Approval Process" (Bull2) is beneficial, as evidenced by their recent FDA approval for GENGLYCOS™ and ongoing BLA reviews. Improvements in "Manufacturing & Delivery Bottlenecks" (Bull3) would also directly aid their gene therapy launches. **Hurt:** * **Biotech '26: Established Pharma (Bear1 & Bear3):** Regulatory uncertainties and shifts in healthcare policies could impact drug approval timelines and reimbursement rates for Ultragenyx's pipeline and existing products. Market volatility and economic uncertainties could affect investment in R&D and delay commercialization, especially for their capital-intensive gene therapy programs. * **Rare Diseases '25: Gene Therapy & Genetic Med (Bear1, Bear2, Bear3):** "Commercial Uptake for Gene Therapies Disappoints" (Bear1) is a risk, as provider hesitancy or reimbursement delays could slow revenue ramps. "Safety or Durability Events Spark FDA Reversal" (Bear2) is a constant risk for gene therapies, potentially leading to clinical holds or more conservative regulatory stances. "Cost-Sharing Burden Shifts to Manufacturers" (Bear3) due to policies like the IRA could increase pricing pressure over time.
3 Main Long-Term Bull Details
- Robust Pipeline of First-Ever Treatments: Ultragenyx has a strong pipeline, particularly in gene therapies (GENGLYCOS™ for GSD Ia, UX-111 for Sanfilippo A syndrome) and an advanced ASO program (GTX-102 for Angelman syndrome), which represent potential first-ever treatments for devastating rare diseases with high unmet needs. Successful approvals and launches of these therapies could significantly expand their market impact and revenue base.
- Proven Commercial Execution and Global Infrastructure: The company has a demonstrated track record of successful commercialization for its existing rare disease products (Crysvita, DOJOLVI, Evkeeza, MEPSEVII) across North America, Latin America, Europe, and Asia. This established global infrastructure provides a strong foundation for efficiently launching and scaling new therapies.
- Path to Profitability and Strategic Capital Allocation: Ultragenyx has a clear path to profitability in 2027, driven by continued double-digit revenue growth from current products, contributions from new launches, and disciplined expense management. The potential monetization of Priority Review Vouchers (PRVs) from gene therapy approvals offers a non-dilutive capital source to bolster their balance sheet.
3 Main Long-Term Bear Details
- Regulatory and Clinical Trial Risks: Despite recent successes, the development of rare disease therapies, especially gene therapies, carries inherent risks. Potential setbacks in clinical trials (e.g., UX143 for osteogenesis imperfecta not hitting primary endpoints), unexpected safety signals, or delays/rejections from regulatory agencies (FDA, MHRA) could significantly impact the pipeline and future revenue.
- Commercial Uptake and Reimbursement Challenges for Gene Therapies: While the Medicare cap is a positive, the high cost of gene therapies can still lead to challenges in commercial uptake, provider hesitancy, and complex, country-by-country reimbursement negotiations. Slower-than-expected ramps for new gene therapy launches could impact their path to profitability.
- Intense Competition and Market Share Erosion: The rare disease space is attracting increasing competition from other biotech and pharmaceutical companies. While Ultragenyx aims for first-in-class treatments, future competitors or alternative therapies could emerge, potentially eroding market share or pressing pricing for their products.
- Competitors And Differentiation
- While specific competitors are not named in the transcript, Ultragenyx operates in the highly competitive rare disease and gene therapy space. Competitors would include other biopharmaceutical companies developing treatments for rare genetic conditions, such as those focusing on enzyme replacement therapies, small molecules, or other gene therapies. Ultragenyx differentiates itself through: * **Focus on Ultra-Rare Diseases:** They target diseases with significant unmet needs, often aiming to be the first to develop treatments. * **Diverse Pipeline and Modalities:** Their pipeline includes enzyme replacement therapies, antisense oligonucleotides (ASOs), and gene therapies, demonstrating a broad scientific approach. * **Global Commercial Infrastructure:** They have an established global commercial team experienced in navigating the complexities of rare disease patient finding, reimbursement, and field execution across multiple regions. * **First-Ever Treatments:** Their pipeline includes potential "first-ever treatments" for devastating diseases like GSD Ia and Sanfilippo syndrome type A, providing a strong competitive edge if approved.
- Recent Performance & What The Market'S Focused On
- Ultragenyx reported a strong second quarter of 2026, achieving its highest quarterly revenue in company history at $214 million. This performance supports their reaffirmed full-year revenue guidance. The company reported a net loss of $92 million for the quarter and had $436 million in cash equivalents and marketable securities as of June 30, 2026. The market is intensely focused on three major upcoming catalysts in the second half of 2026: * **PDUFA date for DTX-401 (GSD Ia):** August 23rd, 2026 (recently approved as GENGLYCOS™). * **PDUFA date for UX-111 (Sanfilippo A syndrome):** September 19th, 2026. * **Top-line Phase III data readout for GTX-102 (Angelman syndrome):** Expected in the September or October timeframe. These events are considered pivotal for the company's growth and future valuation.
- Revenue Segments And Estimated Mix
- Crysvita — Mix: ~72.9%; Source: Q2 2026 transcript; Trend: Strong rebound in orders, steady growth in underlying demand, 50% growth in Latin America/Turkey patients to 1,000, over 100 patients in Turkey.
- DOJOLVI — Mix: ~12.6%; Source: Q2 2026 transcript; Trend: Consistent with steady demand growth, ~30 start forms in North America, ~675 patients on reimbursed therapy, ~300 patients in Europe via early access, notable growth in MENA, strong start in Japan.
- Evkeeza — Mix: ~9.8%; Source: Q2 2026 transcript; Trend: 50% growth over Q2 2025, demand continues to build, >500 patients across 25 countries outside U.S.
- MEPSEVII — Mix: ~4.7%; Source: Q2 2026 transcript; Trend: Continued treatment of patients in this ultra-rare indication.
- Product Brands
- Crysvita
- DOJOLVI
- Evkeeza
- MEPSEVII
- GENGLYCOS™ (DTX-401)
- UX-111
- GTX-102 (apazunersen)
- UX143 (setrusumab)
- DTX-301
- UX701
- UX053
Bull / Bear DetailsUltragenyx (RARE) presents a compelling investment case as of 2026-09-01, driven by strong commercial execution of its rare disease portfolio and significant pi
Thesis
Ultragenyx (RARE) presents a compelling investment case as of 2026-09-01, driven by strong commercial execution of its rare disease portfolio and significant pipeline advancements. The recent FDA approval of GENGLYCOS (DTX-401) for GSD 1A, coupled with the imminent PDUFA for UX-111 and upcoming Angelman syndrome data, positions the company for accelerated growth and a clear path to profitability by 2027. While the setback for setrusumab is a concern, the overall outlook is bullish.
Bull case
Ultragenyx demonstrated strong commercial execution in Q2 2026, achieving the highest quarterly revenue in company history and reaffirming full-year guidance. The global commercial infrastructure continues to effectively expand access and find new patients for its marketed products, including Crysvita, DOJOLVI, Evkeeza, and MEPSEVII, driving consistent double-digit revenue growth and supporting the path to profitability by 2027.
The company has achieved a significant milestone with the FDA approval of GENGLYCOS (DTX-401) for GSD 1A on August 23, 2026, representing a first-ever treatment for a disease with high unmet need. Additionally, the PDUFA date for UX-111 for Sanfilippo A syndrome is set for September 19th, with strong launch readiness and plans to monetize Priority Review Vouchers, providing non-dilutive capital.
The upcoming top-line Phase III ASPIRE study data readout for GTX-102 in Angelman syndrome, expected in September or October, is a major catalyst. The study is powered for clinically meaningful results across Bayley-4 cognition and the sensitive Multi-Domain Responder Index (MDRI). Long-term Phase I/II data has shown sustained meaningful improvements and a consistent safety profile, indicating strong potential.
Bear case
The clinical development of setrusumab (UX143) for osteogenesis imperfecta faced a setback, with Phase III studies failing to meet primary endpoints for fracture reductions. While the FDA is open to alternative fracture analysis, additional clinical data is required, and the MHRA may necessitate a new randomized study, highlighting ongoing regulatory and clinical risks for pipeline assets.
Despite robust launch preparations, the commercial uptake of newly approved gene therapies like GENGLYCOS (DTX-401) and potentially UX-111 could face challenges. These include complexities in reimbursement, potential hesitancy from providers, and ensuring broad patient access, which could impact the revenue ramp and potentially delay the company's stated 2027 profitability target.
Ultragenyx's pipeline, while promising, has a concentration in rare and ultra-rare diseases, making it susceptible to significant impacts from any further clinical failures or regulatory delays. The high investment required for these specialized therapies means that setbacks in key programs could disproportionately affect the company's growth trajectory and overall valuation.
Bull / Bear Case
- Bear Case
- The clinical development of setrusumab (UX143) for osteogenesis imperfecta has faced a setback, with Phase III studies failing to meet primary endpoints for fracture reductions, and additional clinical data or a new randomized study may be required by regulators, highlighting ongoing pipeline risks. Despite robust launch preparations, the commercial uptake of newly approved gene therapies like GENGLYCOS (DTX-401) and potentially UX-111 could encounter challenges related to complex reimbursement, provider hesitancy, and ensuring broad patient access, potentially impacting revenue ramp and delaying the 2027 profitability target. Furthermore, Ultragenyx's valuation appears stretched, with a current P/S ratio of approximately 3.6x, which is above its estimated fair P/S of 2.6x, despite trading below the broader biotech industry average.
- Bull Case
- Ultragenyx demonstrates strong commercial execution, achieving record Q2 2026 revenue and reaffirming full-year guidance for its existing rare disease portfolio, including Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. The company has secured FDA accelerated approval for GENGLYCOS (DTX-401) for GSD 1A, marking its first gene therapy approval and providing a valuable Priority Review Voucher. An imminent PDUFA date for UX-111 for Sanfilippo A syndrome (September 19th) and upcoming Phase III data for GTX-102 in Angelman syndrome (September/October) represent significant near-term catalysts. Ultragenyx maintains a clear path to profitability by 2027, driven by continued revenue growth, disciplined expense management, and the monetization of PRVs, leveraging its established global commercial infrastructure for efficient new product launches.
- More Compelling & Why
- Bear. Despite recent positive catalysts, the current P/S ratio of approximately 3.6x is above its estimated fair value of 2.6x, suggesting the stock may be overvalued on a sales basis. The strongest argument for the bear case is the execution risk and commercial uptake challenges associated with launching multiple high-cost gene therapies, coupled with the setback for setrusumab which highlights ongoing pipeline risks. My view would flip to bullish if the company demonstrates strong, rapid commercial uptake for GENGLYCOS and UX-111, significantly exceeding initial revenue expectations, and if GTX-102 Phase III data is unequivocally positive, leading to a re-rating of its fair value.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Monetization of Priority Review Vouchers (PRVs) from Genglycos (DTX-401) and potentially UX-111 Approvals | The sale of PRVs provides non-dilutive capital, bolstering the balance sheet and contributing significantly to the company's stated path to profitability in 2027. | Ultragenyx's announcement of the sale of PRVs associated with Genglycos (DTX-401) and, if approved, UX-111, including the sale price. This would occur after regulatory approval of each asset. | Successful monetization of PRVs at a favorable price (e.g., >$100M per voucher) = bullish signal, providing significant non-dilutive cash. Delays in monetization or lower-than-expected sale price = bearish signal, impacting balance sheet strength and profitability timeline. | Ultragenyx press releases, SEC filings (Form 8-K), subsequent quarterly financial reports. Expected after each respective approval. | Industry news on PRV sales and market prices (e.g., Rocket Pharmaceuticals recently sold a PRV for $180 million in April 2026). | BioPharma Dive: Analysis of PRV market and recent sale prices. |
| FDA Accelerated Approval of Genglycos (DTX-401) for Glycogen Storage Disease Type Ia (GSD 1A) and Receipt of Priority Review Voucher | This approval, received on August 19/20, 2026, marks Ultragenyx's first gene therapy approval, validating its platform and addressing a significant unmet medical need. It is a major revenue driver and a key step towards 2027 profitability, further bolstered by the accompanying Priority Review Voucher (PRV). | The official announcement from Ultragenyx or the FDA regarding the Biologics License Application (BLA) decision for DTX-401 (Genglycos), which occurred around August 19-20, 2026. Subsequently, watch for news regarding the monetization of the associated PRV. | FDA accelerated approval = bullish signal, indicating market entry for a first-in-class gene therapy and a significant non-dilutive capital source from the PRV. | Ultragenyx press releases, SEC filings (Form 8-K), FDA website. The approval was announced on or around August 19-20, 2026. | Google News alerts for "Ultragenyx Genglycos FDA approval" or "DTX-401 approval". Relevant subreddits like r/biotech or r/pharmaceuticals. | EvaluatePharma: DTX-401 regulatory status updates and market entry analysis. BioPharma Dive: Analysis of PRV market and recent sale prices. |
| Continued Double-Digit Revenue Growth from Commercial Products (Crysvita, DOJOLVI, Evkeeza, MEPSEVII) | Sustained growth from existing products is crucial for maintaining financial health, funding pipeline development, and achieving the 2027 profitability target. Strong commercial execution reinforces the company's ability to maximize market opportunities. | Quarterly revenue reports for Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. Specifically, look for continued double-digit year-over-year growth and reaffirmation or upward revision of full-year revenue guidance. The next report will be for Q3 2026. | Consistent double-digit growth and strong demand (e.g., new patient additions, order patterns) = bullish signal, confirming commercial execution. Significant deceleration in growth or downward revision of guidance = bearish signal, indicating market saturation or competitive pressure. | Ultragenyx quarterly earnings reports and conference calls (next expected Q3 2026 results in late October/early November 2026). | Google Trends: Search interest for "Crysvita", "DOJOLVI", "Evkeeza", "MEPSEVII" in key markets. Company investor relations section for patient updates. | IQVIA/Symphony Health: Prescription data and market share for Crysvita, DOJOLVI, Evkeeza, MEPSEVII. |
| Top-line Phase III ASPIRE Study Data Readout for GTX-102 in Angelman Syndrome | This is the most advanced clinical ASO program for Angelman syndrome. Positive data would significantly de-risk the program, paving the way for potential regulatory submission and future market opportunity in a disease with no approved treatments. | Ultragenyx's announcement of top-line results from the Phase III ASPIRE study, including Bayley-4 cognitive raw score and Multi-Domain Responder Index (MDRI) outcomes. Expected in September or October 2026. | Statistically significant improvement in either Bayley-4 cognition (P value <= 0.04) or MDRI (P value <= 0.01) = bullish signal, indicating potential for successful BLA. Failure to meet statistical significance on either endpoint = bearish signal, indicating potential delays or need for additional studies. | Ultragenyx press releases, investor presentations, scientific conferences. Expected in September or October 2026. | ClinicalTrials.gov: GTX-102 study status updates. Biotech news outlets covering clinical trial results. | EvaluatePharma: GTX-102 clinical trial success probability. Clinical trial intelligence platforms. |
| FDA Approval of UX-111 for Sanfilippo Syndrome Type A (PDUFA September 19, 2026) | This would be Ultragenyx's second potential gene therapy approval, further expanding their rare disease portfolio and reinforcing their leadership in genetic medicines. Given a prior Complete Response Letter (CRL) in July 2025, a positive decision would significantly de-risk the program and validate the company's regulatory strategy. | Official announcement from Ultragenyx or the FDA regarding the Biologics License Application (BLA) decision for UX-111. The PDUFA action date is September 19th, 2026. | FDA approval = bullish signal, indicating market entry for another first-in-class gene therapy and overcoming prior regulatory hurdles. Complete Response Letter (CRL) or delay = bearish signal, raising further concerns about the regulatory pathway and timeline for this asset. | Ultragenyx press releases, SEC filings (Form 8-K), FDA website. Expected around September 19th, 2026. | Google News alerts for "Ultragenyx UX-111 FDA", "Sanfilippo A gene therapy approval". Relevant patient advocacy forums. | EvaluatePharma: UX-111 regulatory status updates and probability of approval. |
Key Reported Metrics, Reratings Triggers & ResultsThe success of this pivotal Phase III trial is crucial for validating Ultragenyx's ASO platform and expanding its pipeline, significantly impacting future growt
Upcoming print · 2026-11-03
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| GTX-102 (Angelman syndrome) Phase III Data Readout | N/A | The success of this pivotal Phase III trial is crucial for validating Ultragenyx's ASO platform and expanding its pipeline, significantly impacting future growth prospects and investor confidence. |
| UX-111 (Sanfilippo A syndrome) Approval/Launch | N/A | FDA approval and initial commercialization efforts for this gene therapy are a major catalyst, representing a first-ever treatment for a devastating rare disease and a new revenue stream. |
| Total Revenue | 28.5% | Reflects overall commercial execution and is critical for the company's reaffirmed full-year guidance and stated path to profitability in 2027. Investors will watch for sustained double-digit growth. |
Key QuestionsWill Ultragenyx secure FDA approval for UX-111 (Sanfilippo Syndrome Type A) by its September 19th PDUFA date, and what will be the initial commercial uptake if
Will Ultragenyx secure FDA approval for UX-111 (Sanfilippo Syndrome Type A) by its September 19th PDUFA date, and what will be the initial commercial uptake if approved?
- Question 2
Will the Phase III ASPIRE study for GTX-102 (Angelman Syndrome) demonstrate statistically significant efficacy on its primary endpoints (Bayley-4 cognition or MDRI) in the September/October readout, supporting a path to regulatory submission?
- Question 3
How will the initial commercial launch of Genglycos (DTX-401) and the continued growth of existing products (Crysvita, Dojolvi, Evkeeza, Mepsevii) contribute to Ultragenyx's reaffirmed 2026 revenue guidance and its path to profitability in 2027, including the monetization of Priority Review Vouchers?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Continued strong commercial execution and revenue growth from current products:** Management highlighted the highest quarterly revenue in company history and reaffirmed full-year guidance, emphasizing the global infrastructure's role in finding new patients and expanding access for Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. 2. **Successful launch of two potential gene therapies:** Ultragenyx is preparing for the anticipated launches of DTX-401 for GSD 1A and UX-111 for Sanfilippo A syndrome, with PDUFA dates in August and September, respectively. These therapies represent first-ever treatments for diseases with significant unmet needs. 3. **Advancing the pipeline and achieving profitability in 2027:** The company is focused on the upcoming Phase III data readout for GTX-102 in Angelman syndrome in September or October, and outlined a clear path to profitability in 2027 through continued revenue growth, expense discipline, and monetization of Priority Review Vouchers. | Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management highlighted strong commercial execution, achieving the highest quarterly revenue in company history, and reaffirmed full-year guidance. The tone was optimistic regarding significant upcoming catalysts, including two potential gene therapy approvals and launches (DTX-401 and UX-111) and the Phase III data readout for GTX-102 in Angelman syndrome. The company also reiterated a clear path to profitability in 2027, driven by continued product growth, disciplined expense management, and PRV monetization. There was a strong emphasis on addressing urgent unmet needs in rare diseases. | Prior Quarter'S Y/Y Growth By SegmentFor Q1 2026, total revenue was $136 million, representing a -2.16% year-over-year change compared to Q1 2025. Crysvita revenue was $93 million, a -9.71% year-over-year change. DOJOLVI revenue was $18 million, a 5.88% year-over-year change. Evkeeza revenue was $18 million, a 63.64% year-over-year change. MEPSEVII revenue was $7 million, a -16.54% year-over-year change. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **GTX-102 (Angelman syndrome) endpoints and statistical powering:** Analysts questioned the sufficiency of one endpoint for filing, the clinical meaningfulness of the endpoints, the sensitivity of the Multi-Domain Responder Index (MDRI), and the alpha allocation. Management responded that the FDA agreed to the alpha sharing, meaning either endpoint can be positive. They are powered for clinically meaningful results, noting a 5-6 point change in the Bayley is considered clinically meaningful, and the MDRI only scores clinically meaningful results. They emphasized the MDRI's sensitivity and broader meaning across multiple domains. 2. **GTX-102 (Angelman syndrome) safety profile and discontinuation rates:** Analysts inquired about lower extremity weakness, neuroinflammation, and dropout rates. Management stated the study has continued smoothly without safety issues, they don't expect a different safety profile from what has been seen, and they would not comment on discontinuation rates but noted good persistence of patients long-term after the initial months. 3. **Financials, launch investments, and market size for new therapies:** Analysts asked about the cash balance, potential financing needs, investment required for upcoming launches, and the market size for DTX-401 and UX-111. Management (Howard Horn) stated their focus is on monetizing Priority Review Vouchers (PRVs) for DTX-401 and UX-111 upon approval to bolster the balance sheet. They clarified that launch investments are included in existing R&D and SG&A guidance, leveraging their current infrastructure. Emil Kakkis provided estimated market sizes: approximately 6,000 GSDIa patients globally (1,500-2,000 in the U.S.) and 3,000-5,000 Sanfilippo syndrome patients globally (20-25% in the U.S.), with a focus on younger patients. | Revenue SegmentsTotal revenue for Q2 2026 was $214 million, representing 28.5% year-over-year growth. Crysvita contributed $156 million, with management noting steady growth in underlying demand and strong performance in Latin America and Turkey. DOJOLVI contributed $27 million, consistent with expectations for steady demand growth. Evkeeza contributed $21 million, representing 50% growth over Q2 2025. MEPSEVII contributed $10 million. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketThe commercial team delivered the highest quarterly revenue in the company's history and continues to find new patients and expand access to Crysvita, DOJOLVI, Evkeeza, and MEPSEVII globally. Approximately 50 patients began commercial therapy in the second quarter, bringing the total number of patients on Crysvita to 1,000 in Latin America. In Turkey, over 100 patients are being treated with Crysvita through a named patient program, showing accelerating demand. For DOJOLVI, the North American team generated about 30 start forms, resulting in approximately 675 patients on reimbursed therapy, while in Europe, about 300 patients are being treated through named patient or early access programs, with growth in the MENA region following marketing authorization in Kuwait. DOJOLVI also recently began treating patients in Japan after its listing on the National Health Insurance Drug Price List, representing a meaningful opportunity for continued growth. Evkeeza is treating more than 500 patients across 25 countries outside the U.S., with teams navigating country-by-country reimbursement and early access. For DTX401 (GSDIa), the estimated addressable population is about 6,000 in the developed world, with 1,500-2,000 in the U.S., and for Sanfilippo syndrome, there are 3,000-5,000 globally. | About CompetitionThe transcript does not directly mention specific competitors or competitive dynamics for Ultragenyx's products. However, the broader 'Biotech '26: Established Pharma' theme context notes that increased competition from emerging biotech companies and generic drug manufacturers may erode market share and pressure pricing strategies. | About The Broader IndustryRare disease commercialization requires deep market-by-market expertise, including patient finding, reimbursement navigation, and field execution. The Medicare out-of-pocket cap of $2,000, introduced by the IRA, is considered a significant change for high-cost, one-time therapies, potentially expanding the eligible patient pool and accelerating revenue ramps for gene therapies. The FDA is actively streamlining the gene therapy approval process, with draft guidance confirming CBER-CDER alignment and expanded use of surrogate endpoints, which could improve the probability of success and speed for rare diseases with severe phenotypes. Manufacturing and delivery bottlenecks for gene therapies are being addressed, with leaders showing improvements in AAV delivery, lipid nanoparticle technology, and topical/intramuscular platforms, reducing historical issues with durability, dosing, and immune responses. | Where Things Are HeadedThe second half of 2026 is anticipated to be the most significant period in the company's history, with potential firsts including the first gene therapy approvals for Ultragenyx, the first FDA approvals for two devastating rare diseases, and the first late-stage clinical data in Angelman syndrome. The company aims for profitability in 2027, driven by continued double-digit revenue growth from current products, contributions from potential upcoming launches, disciplined expense management, and monetization of priority review vouchers for DTX401 and UX111 if approved. Ultragenyx is preparing for the parallel launch of two gene therapies, DTX401 and UX111, by working with Qualified Treatment Centers (QTCs) and engaging with payers who recognize the significant unmet need and urgency to treat these diseases. For setrusumab (osteogenesis imperfecta), discussions with the FDA are ongoing, with the agency open to considering alternative approaches to fracture analysis, though additional clinical data may be needed to support a potential BLA. | Updates On ThemeEstablished | Bullish-Leaning Quotes (Short)“The commercial team delivered the highest quarterly revenue in the history of the company.” “The second half of 2026 is poised to be the most significant period in our company's history.” “clear path to profitability in 2027.” “underlying demand for our products remains strong.” “We certainly know what we're doing, and we'll be prepared.” “MDRI was, for example, tenfold more powerful to detect change.” | Bearish-Leaning Quotes (Short)“seasonal factors can cause quarter-to-quarter variability in revenue.” “While neither study hit statistical significance for the primary endpoints of annualized fracture reductions, we did see clear signals of biologic activity.” “a new randomized study may be needed before they would consider reviewing an application for approval.” “additional clinical data would be needed to support a potential BLA.” “At this point, there hasn't been the kind of proof for BMD's predictive value for fractures as there has been for osteogenesis, I'm sorry, for osteoporosis, where it has been accepted.” | HiringUltragenyx plans to leverage its existing global commercial infrastructure, which has been expanded for previous product launches, for the upcoming gene therapy launches. The company anticipates a "measured addition" to its team, indicating strategic, rather than broad, workforce expansion. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-04 | Ultragenyx's Q2 2026 earnings reported record revenue of $214 million, up 28.5% year-over-year, reaffirming full-year guidance and a path to 2027 profitability. Management highlighted strong commercial execution and upcoming gene therapy launches. The stock's 0.39% return (T+2 days), outperforming SPY's 0.25%, indicates a positive market reception, aligning with the company's confident outlook and pipeline catalysts. | Earnings Transcript | Neutral | +0.39% (vs SPY: +0.14%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| RARE_9dfa8b7a | September 19th | 2026-09-19 | 2026-09-19 | FDA PDUFA action date for UX111 for the treatment of Sanfilippo syndrome type A. | This represents a potential first-ever treatment for a devastating neurodegenerative disease with high unmet need, which could lead to a significant new revenue stream and accelerate the next phase of growth for Ultragenyx. | Ticker | 2026-08-04 | earnings_transcript |
| RARE_20076f9b | September or October timeframe | 2026-09-01 | 2026-10-31 | Top-line Phase III data readout from the ASPIRE study for GTX-102 in Angelman syndrome. | This milestone represents the first late-stage clinical data in Angelman syndrome, which could significantly de-risk or re-risk the program and impact future revenue potential and company valuation. | Ticker | 2026-08-04 | earnings_transcript |